BenevolentAI

5 Followers

About

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading...

Ivan Griffin
Co-founder and COO
Rob Quinn
Chief Financial Officer
Anne Phelan
Chief Scientific Officer
Daniel Neil
SVP Artificial Intelligence
Trecilla Lobo
SVP People
Mark Davies
SVP Informatics and Data
Will Scrimshaw
General Counsel
Nikki Robas
VP Drug Discovery
Peter Cox
VP Drug Discovery
Dave Michalovich
VP Precision Medicine
Bryn Williams-Jones
VP Drug Discovery
Ed Savory
VP Drug Discovery
Constantinos Neophytou
VP Engineering
Peter Richardson
VP Pharmacology
Catherine Tucker
VP, Business Development
Rajin Kang
VP Communications

No teams yet!

No jobs yet!

Other announcement

Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38%

Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet on February 4, 2020. Data from the ACTT-2 clinical trial resulted in the FDA granting emergency use authorisation for baricitinib in combination with remdesivir to treat hospitalised COVID-19 patients by November 2020. BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, congratulate Eli Lilly on results from its COV-BARRIER trial in 1,525 hospitalised COVID-19 patients demonstrating baricitinib reduces mortality by 38% (nominal p-value=0.0018), showing the largest clinical effect reported to date for a reduction in mortality in this patient population.[https://www.benevolent.com/news/data-from-eli-lillys-cov-barrier-trial-shows-baricitinib-reduced-deaths-in-hospitalised-covid-19-patients-by-38 ](url)

Partnership announcement

BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target

Novel chronic kidney disease (CKD) target from the partnership enters AstraZeneca’s portfolio AI-generated target was identified through The Benevolent Platform® and AstraZeneca’s scientific expertise and rich datasets ‍ [https://www.benevolent.com/news/benevolentai-and-astrazeneca-achieve-collaboration-milestone-with-novel-ai-generated-chronic-kidney-disease-target ](url)

Other announcement

BenevolentAI announces dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis

BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. https://www.benevolent.com/news/benevolentai-announces-first-patient-dosed-in-its-atopic-dermatitis-clinical-trial

Other announcement

FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI

Baricitinib was identified by researchers at BenevolentAI as a potential treatment for COVID-19 in early February 2020 The FDA authorisation enables immediate use of baricitinib in combination with remdesivir to treat hospitalised COVID-19 patients ACTT-2 data demonstrated baricitinib improved clinical outcomes and increased recovery rates of hospitalised COVID-19 patients There was a 35% lower mortality rate overall in the group taking baricitinib (5.1% vs 7.8%) https://www.benevolent.com/news/fda-grants-emergency-use-authorisation-for-baricitinib-in-hospitalised-covid-19-patients-nine-months-after-initial-hypothesis-was-published-by-benevolentai

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.